Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiauranib + Capecitabine in Advanced TNBC
NCT05336721Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Nov 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of chiauranib in triple-negative breast cancer (TNBC), sponsored by Akeso, Inc. Primary endpoint: Objective Response Rate at 2 years. Started Nov 2021; status: terminated.
02
Drugs
chiauranib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05336721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05336721.